GC Green Cross, known for its blood product 'Aliglo,' announced on May 14 that it has signed a strategic memorandum of understanding (MOU) with global science and technology company Merck Life Science to enhance cooperation in biopharmaceutical development and Good Manufacturing Practice (GMP) production processes.
The signing ceremony took place at Merck's headquarters in Gangnam, Seoul, attended by Kim Young-im, head of Merck Life Science Process Solutions Business, and Shin Woong, head of operations at GC Green Cross.
Under this agreement, GC Green Cross aims to strengthen its supply chain for raw materials necessary for biopharmaceutical production and establish a cooperative system to enhance manufacturing efficiency and supply stability. This strategy targets both the profitable blood products and vaccines market as well as the global rare disease sector.
Merck will provide a comprehensive cooperation system covering everything from raw material procurement to process technology support. The company plans to manage supply chain risks proactively by ensuring a stable supply of products that meet strict quality standards.
The two companies plan to operate regular process consultation meetings to strengthen technical cooperation for manufacturing efficiency. This will facilitate the sharing of the latest process technology information, enhance quality competitiveness, and continuously seek opportunities for joint research and development (R&D).
Shin Woong stated, "This collaboration will strengthen the foundation for producing and supplying essential medicines and treatments for major rare diseases. We will minimize manufacturing risks and enhance quality competitiveness through process optimization and technical cooperation."
* This article has been translated by AI.
Copyright ⓒ Aju Press All rights reserved.